Literature DB >> 24352157

The accuracy of predicting cardiovascular death based on one compared to several albuminuria values.

Gudrun Hatlen1, Solfrid Romundstad2, Stein I Hallan1.   

Abstract

Albuminuria is a well-documented predictor of cardiovascular (CV) mortality. However, day-to-day variability is substantial, and there is no consensus on the number of urine samples required for risk prediction. To resolve this we followed 9158 adults from the population-based Nord-Trøndelag Health Study for 13 years (Second HUNT Study). The predictive performance of models for CV death based on Framingham variables plus 1 versus 3 albumin-creatinine ratio (ACR) was assessed in participants who provided 3 urine samples. There was no improvement in discrimination, calibration, or reclassification when using ACR as a continuous variable. Difference in Akaike information criterion indicated an uncertain improvement in overall fit for the model with the mean of 3 urine samples. Criterion analyses on dichotomized albuminuria information sustained 1 sample as sufficient for ACR levels down to 1.7 mg/mmol. At lower levels, models with 3 samples had a better overall fit. Likewise, in survival analyses, 1 sample was enough to show a significant association to CV mortality for ACR levels above 1.7 mg/mmol (adjusted hazard ratio 1.37; 95% CI 1.15-1.63). For lower ACR levels, 2 or 3 positive urine samples were needed for significance. Thus, multiple urine sampling did not improve CV death prediction when using ACR as a continuous variable. For cutoff ACR levels of 1.0 mg/mmol or less, additional urine samples were required, and associations were stronger with increasing number of samples.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352157     DOI: 10.1038/ki.2013.500

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  2 in total

1.  Albuminuria is associated with elevated acute phase reactants and proinflammatory markers in HIV-infected patients receiving suppressive combination antiretroviral therapy.

Authors:  Pichaya O-charoen; Lishomwa C Ndhlovu; Louie Mar A Gangcuangco; Sheila M Keating; Philip J Norris; Roland C K Ng; Brooks I Mitchell; Cecilia M Shikuma; Dominic C Chow
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

2.  Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.

Authors:  Hugh Gallagher; Jennifer Dumbleton; Tom Maishman; Amy Whitehead; Michael V Moore; Ahmet Fuat; David Fitzmaurice; Robert A Henderson; Joanne Lord; Kathryn E Griffith; Paul Stevens; Maarten W Taal; Diane Stevenson; Simon D Fraser; Mark Lown; Christopher J Hawkey; Paul J Roderick
Journal:  Trials       Date:  2022-04-21       Impact factor: 2.728

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.